Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.78 |
| ▸ | HPGD | P15428 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.78 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.76 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.76 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | ACP1 | P24666 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.60 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.60 |
| ▸ | PDXK | O00764 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal SCHEMBL29906 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL29389313 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL5416120 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL27587627 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL4668019 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL8533734 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL50601 | 0.86 | TRIM24 (1.00) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL2527773 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL30963032 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL27968521 | 0.86 | KDM4E (0.97) | KDM4EALDH1A1LMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345299-A1 | COMBINATION AND COMPOSITION COMPRISING NICOTINIC ACID OR DERIVATIVE THEREOF AND FATTY ACID OR DERIVATIVE THEREOF | T OMEGA AS (NO) | 2025-11-13 | — | — | US | disclosed |
| US-20240390412-A1 | USE OF DEXTRAN SULFATE | TX MEDIC AB (SE) | 2024-11-28 | — | — | US | disclosed |
| US-12076337-B2 | Method for dissolving scars with dextran sulfate | TX MEDIC AB (SE) | 2024-09-03 | — | — | US | disclosed |
| US-20230120722-A1 | METHOD FOR DISSOLVING SCARS WITH DEXTRAN SULFATE | TX MEDIC AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11534457-B2 | Use of dextran sulfate | TX MEDIC AB (SE) | 2022-12-27 | — | — | US | disclosed |
| US-20220128542-A1 | TREATMENT EFFICIENCY EVALUATION | TX MEDIC AB (SE) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345299-A1 | COMBINATION AND COMPOSITION COMPRISING NICOTINIC ACID OR DERIVATIVE THEREOF AND FATTY ACID OR DERIVATIVE THEREOF | HADHA, HAGH, HADHB | KDM4E 3678/4885ALDH1A1 1208/4885LMNA 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.